doi: 10.1016/j.xfss.2024.03.001
This theoretical considerations lost relevance when they were contrasted with the results obtained with the treated children
doi: 10.1007/s00580-013-1818-1 6
a first therapy (e.g., prophylactic or therapeutic agent) can be administered prior to (e.g., 1 minute, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 1 minute, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy (e.g., prophylactic or therapeutic agent) to a subject which had, has, or is susceptible to a hyperproliferative cell disorder, especially cancer

3.1.4 Nrf2/Slc7a11/GPX4 axis and myocardial injury In ischemia-reperfusion injury (IRI), a well-established model for myocardial injury, ozone pre-treatment mitigates myocardial ferroptosis by activating the Nrf2/solute carrier family 7 member 11 (Slc7a11)/GPX4 axis
Intravesical treatments with heparin, hyaluronic acid, chondroitin sulfate, bacillus Calmette-Guerin, dimethylsulfoxide, and resiniferatoxin have been effective in treating IC/BPS, but the effects were not durable (Hanno et al., 2015)